View Older Stories View More Recent Stories

Jan 10, 2017 04:08PM Merck (MRK) Announces FDA Accepts for Review the sBLA for KEYTRUDA; PDUFA Date May 10, 2017
Jan 10, 2017 04:06PM Merck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-Squamous Non-Smal
Jan 9, 2017 08:05AM Incyte (INCY), Merck (MRK) to Advance Clinical Development of Epacadostat with KEYTRUDA Combo
Jan 9, 2017 08:00AM Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)
Jan 6, 2017 08:00AM Merck to Participate at the 35th Annual J.P. Morgan Healthcare Conference
Jan 3, 2017 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2016 Sales and Earnings Conference Call on February 2
Dec 19, 2016 07:01AM Merck (MRK) Announces KEYTRUDA Approval in Japan to Treat Advanced NSCLC
Dec 19, 2016 07:00AM KEYTRUDA® (pembrolizumab) Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express High Levels of PD-L1
Dec 16, 2016 07:28AM Merck (MRK) KEYTRUDA Gains Positive CHMP Recommendation for the First-Line Treatment of Patients with Metastatic NSCLC
Dec 16, 2016 07:26AM European Medicines Agency’s CHMP Recommends Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD
Dec 12, 2016 07:01AM Merck (MRK) and Eisai Reports Encourating Phase 1b/2 KEYTRUDA/HALAVEN Combo Results
Dec 12, 2016 07:00AM Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck’s KEYTRUDA® (pembrolizumab) and Eisai’s HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Canc
Dec 12, 2016 07:00AM Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck's KEYTRUDA® (pembrolizumab) and Eisai's HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer P
Dec 7, 2016 06:11AM Merck (MRK) Announces Positive HRQoL Data from KEYTRUDA Phase 3 KEYNOTE-024 Study
Dec 7, 2016 02:45AM KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Dec 6, 2016 09:00AM Merck's Consumer Health Business Drives Consumer-Centric, Purposeful Innovation
Dec 6, 2016 08:24AM Merck (MRK) Updates on KEYTRUDA Phase 1b KEYNOTE-028 Study; Clinical Activity, Durable Responses Observed
Dec 6, 2016 08:20AM Updated KEYTRUDA® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
Dec 6, 2016 08:00AM Merck to Participate at the Citi 2016 Global Healthcare Conference
Dec 6, 2016 06:21AM Merck (MRK) to Present Strong Results from Two KEYTRUDA Studies in r/r cHL
Dec 5, 2016 07:30PM KEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology
Dec 5, 2016 10:45AM Merck (MRK) KEYTRUDA Showed 41% ORR
Dec 5, 2016 10:42AM Updated KEYTRUDA® (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology
Dec 5, 2016 08:17AM Merck (MRK) Lists Cancer Genetics (CGIX) as KEYTRUDA National Reference Laboratory
Dec 1, 2016 07:07AM Merck's (MRK) sBLA for KEYTRUDA Accepted by U.S. FDA in r/r CHL
Dec 1, 2016 07:00AM FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck’s KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma
Nov 30, 2016 07:03AM Merck (MRK) to Present New KEYTRUDA Data at Upcoming Conference
Nov 30, 2016 07:00AM New KEYTRUDA® (pembrolizumab) Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies
Nov 29, 2016 08:21AM FDA Accepts BLA for Avelumab for Treatment of MCC for Priority Review (PFE)
Nov 29, 2016 08:17AM FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
Nov 29, 2016 07:00AM Actress Bellamy Young, Merck, and Leading Lung Cancer Advocates Urge Those Impacted by Lung Cancer to Test. Talk. Take Action.
Nov 28, 2016 07:02AM Merck (MRK) Announces FDA Priority Review for KEYTRUDA sBLA in Microsatellite Instability-High Cancer
Nov 28, 2016 07:00AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA® (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer
Nov 23, 2016 09:24AM Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)
Nov 22, 2016 01:22PM Merck Announces Increased Quarterly Dividend
Nov 22, 2016 08:04AM QuintilesIMS (Q) Enters anti-Cancer Treatment Collaborations with Leading Pharma Companies (PFE) (BMY)
Nov 22, 2016 07:03AM Merck (MRK) to Present New KEYTRUDA Investigational Use Data at ASH 2016
Nov 22, 2016 07:00AM New KEYTRUDA® (pembrolizumab) Data in Blood Cancers to be Presented at 58th Annual Meeting of the American Society of Hematology
Nov 14, 2016 07:14AM OpGen (OPGN), Merck (MRK) Enter Rapid Diagnostics, IT Products Development Collaboration
Nov 14, 2016 06:52AM Merck (MRK) Announces Upcoming Presentation of Strong ZEPATIER Data in Certain HCV Genotypes
Nov 14, 2016 06:30AM Merck (MRK) Announces Significant Data from KEYTRUDA in Adv. Bladder Cancer
Nov 14, 2016 06:29AM Merck (MRK) Presents Results from Three MK-3682B Phase 2s; High SVR Rates Noted
Nov 13, 2016 08:00AM Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
Nov 12, 2016 11:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer
Nov 12, 2016 08:00AM Merck Announces Presentation of New Findings for ZEPATIER™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting®
Nov 7, 2016 07:07AM Merck (MRK) Announces New KEYTRUDA Data to be Presented at SITC 2016 Annual Meeting
Nov 7, 2016 07:00AM New KEYTRUDA® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting
Nov 2, 2016 04:30PM Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine
Oct 31, 2016 03:00AM European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Oct 26, 2016 08:00AM Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ID Week 2016
View More Recent Stories View Older Stories